{"id":1020131,"date":"2026-11-11T17:51:23","date_gmt":"2026-11-11T22:51:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/"},"modified":"2026-11-11T17:51:23","modified_gmt":"2026-11-11T22:51:23","slug":"alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/","title":{"rendered":"Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update"},"content":{"rendered":"<div class=\"mw_release\">\n<p>REYKJAVIK, Iceland, Nov.  11, 2026  (GLOBE NEWSWIRE) &#8212; Alvotech (NASDAQ: ALVO; ALVO-SDB) (\u201cAlvotech\u201d or the \u201cCompany\u201d), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the nine months to September 30, 2026, and provided a business update.<\/p>\n<p>Supplemental information, including the management presentation providing additional details and a business update, is available on our website: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MkzTwN5x74HdjB6kMBV9eEkfMv_3O8HeCIxo6fRXXFogZ4UVR03PT1KhOntsVMdqmVBmnO4cj54PEFE6QaK01qsbCcbAxZTzAd8aCnVeKMdO_QhnTaNrRVfXXLyKxCWs\" rel=\"nofollow\" target=\"_blank\">https:\/\/alvotech.com\/financials<\/a>.<sup>1<\/sup><\/p>\n<p>\n        <strong>Financial Highlights for the Nine Months to September 30, 2026<sup>2<\/sup><\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Adjusted total revenue<sup>2<\/sup> was $323.4 million compared to $420.0 million in the same period last year.<\/li>\n<li>Gross Margin was 54% compared to 59% in the same period last year.<\/li>\n<li>Adjusted EBITDA<sup>2<\/sup> was $78.3 million compared to $68.0 million in the same period last year.<\/li>\n<li>Reported cash balance at the end of the period was $61.5 million compared to $172.4 million on December 31, 2025.<\/li>\n<\/ul>\n<table style=\"border-collapse: collapse;margin-left:6.75pt;margin-right:6.75pt;width:98%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:40%;width:40%;min-width:40%;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:7%;width:7%;min-width:7%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\n            <strong>9M 2026<\/strong>\n          <\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:7%;width:7%;min-width:7%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\n            <strong>9M 2025<\/strong>\n          <\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%\">\u00a0<\/td>\n<td style=\"max-width:8%;width:8%;min-width:8%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>Change<\/strong>\n          <\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:7%;width:7%;min-width:7%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\n            <strong>3Q 2026<\/strong>\n          <\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:7%;width:7%;min-width:7%;border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\n            <strong>3Q 2025<\/strong>\n          <\/td>\n<td style=\"max-width:1%;width:1%;min-width:1%;border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%\">\u00a0<\/td>\n<td style=\"max-width:8%;width:8%;min-width:8%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>Change<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 30.0px;border-bottom: solid black 1pt\">Product and Service Revenue<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">164.2<\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">237.4<\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">-30.8%<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">58.2<\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">32.6<\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">78.3%<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 30.0px;border-bottom: solid black 1pt\">License and Other Revenue<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">158.9<\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">182.4<\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">-12.9%<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">53.2<\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">81.1<\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">-34.4%<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 30.0px;border-bottom: solid black 1pt\">Other Income<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">0.4<\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">0.3<\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">45.2%<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">0.2<\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">0.1<\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">39.8%<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 20.0px;border-bottom: solid black 1pt\">\n            <strong>Total revenue<\/strong>\n          <\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\n            <strong>323.4 <\/strong>\n          <\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\n            <strong>420.0 <\/strong>\n          <\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">-23.0%<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\n            <strong>111.6 <\/strong>\n          <\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\n            <strong>113.9 <\/strong>\n          <\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">-2.0%<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 20.0px;border-bottom: solid black 1pt\">\n            <strong>Gross margin<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\n            <strong>54%<\/strong>\n          <\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\n            <strong>59%<\/strong>\n          <\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\n            <strong>54%<\/strong>\n          <\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\n            <strong>69%<\/strong>\n          <\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 20.0px;border-bottom: solid black 1pt\">\n            <strong>Adjusted EBITDA<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\n            <strong>78.3 <\/strong>\n          <\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\n            <strong>68.0 <\/strong>\n          <\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">15.1%<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\n            <strong>31.5 <\/strong>\n          <\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\n            <strong>14.4 <\/strong>\n          <\/td>\n<td style=\"border-bottom: solid black 1pt\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">118.8%<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong><br \/>\n          <br \/>Recent Business Highlights<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>The FDA accepted Alvotech\u2019s Biologics License Application (BLA) for AVT80, a proposed biosimilar to Entyvio<sup>\u00ae<\/sup> (vedolizumab) in prefilled syringe and autoinjector presentations for subcutaneous administration. Alvotech is responsible for development and manufacturing, while Teva has licensed the U.S. commercial rights.<\/li>\n<li>Alvotech and its commercial partner Advanz Pharma submitted the first known regulatory submission worldwide for a proposed biosimilar to Eylea HD (aflibercept 8 mg). The marketing application was submitted to the European Medicines Agency.<\/li>\n<li>Alvotech signed an agreement with Lotus Pharmaceuticals covering the commercialization rights in the U.S. and selected Asian markets for AVT34, a proposed biosimilar to Imfinzi<sup>\u00ae<\/sup> (durvalumab) and AVT87, a proposed biosimilar to Hemlibra<sup>\u00ae <\/sup>(emicizumab). Alvotech retains the right to also commercialize both products directly in the U.S. alongside Lotus.<\/li>\n<li>Alvotech and LOTTE Biologics entered a long-term partnership under which LOTTE biologics will manufacture drug substance for multiple biosimilars at its facility in Syracuse, New York. The arrangement expands Alvotech\u2019s U.S. manufacturing footprint, adding additional capacity and flexibility to its global supply network.<\/li>\n<li>The U.S. Food and Drug Administration (FDA) approved a new process for manufacturing Simlandi<sup>\u00ae<\/sup>, Alvotech\u2019s biosimilar to Humira<sup>\u00ae<\/sup>, in the Reykjavik manufacturing facility. The new process more than doubles output per batch, allowing the same quantity of Simlandi to be produced in fewer batches and thus freeing up manufacturing capacity for other products.<\/li>\n<li>The FDA also approved the production of drug substance for Simlandi<sup>\u00ae<\/sup> in a second production suite at Alvotech\u2019s Reykjavik site, resulting in added flexibility and increased manufacturing capacity.<\/li>\n<\/ul>\n<p>\n        <strong>Lisa Graver, Chief Executive Officer, comments: <\/strong>\n      <\/p>\n<p>\n        <em>\u201cOur commercial performance strengthened in the third quarter, with product and service revenue reaching $58 million, up 6% sequentially and 78% year over year. Following the completion of the manufacturing improvement program in the first half of the year, we are continuing to increase supply to meet strong underlying demand across our markets. <\/em>\n      <\/p>\n<p>\n        <em>\u201cThe two recent FDA approvals for Simlandi at our Reykjav\u00edk facility represent significant milestones. The addition of a second approved manufacturing suite and an enhanced process that more than doubles output per batch give us greater capacity and operational flexibility to support our expanding commercial portfolio. <\/em>\n      <\/p>\n<p>\n        <em>\u201cWe have also made important advances in our pipeline, including regulatory milestones for our proposed biosimilars to Entyvio and high-dose Eylea. Our agreement with Lotus creates an opportunity for Alvotech to participate directly in U.S. commercialization, while our partnerships with LOTTE Biologics and Fujifilm strengthen our future manufacturing network. Our priority now is to translate this progress into planned product deliveries in the fourth quarter, while continuing to build the platform for long-term growth.\u201d<\/em>\n      <\/p>\n<p>\n        <strong>Outlook for the Full Year 2026<\/strong>\n      <\/p>\n<p>Alvotech maintains its full-year 2026 guidance for total revenue of $650-$700 million and EBITDA of $180-$220 million, with performance now expected toward the lower end of the range. The Company remains focused on executing planned product deliveries in the fourth quarter, as production and commercial supply continue to ramp up following the manufacturing improvement program completed in the first half of the year.<\/p>\n<p>\n        <strong>Invitation to management presentation<\/strong>\n      <\/p>\n<p>Join us to listen to the live audio webcast at 8:00 AM EST (13:00 GMT, 14:00 CET) on Thursday, November 12, 2026. Materials for the webcast are available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MkzTwN5x74HdjB6kMBV9eEkfMv_3O8HeCIxo6fRXXFrAzvZh3xhJXwcSz2xdegJGfy9ixWMUNVy0rlUqoGenJUZGOCFBjaJLv5RWiPeME_UQ5AIaVQ1fuJPUsaFLCINk\" rel=\"nofollow\" target=\"_blank\">https:\/\/alvotech.com\/financials<\/a>.<\/p>\n<p>\n        <strong>The audio webcast will be accessible via the following link:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MkzTwN5x74HdjB6kMBV9ePAiqm8a-Et5AoRHuidMqe2OAD6alkM3Dt_Mrd0LrMSjp3gq2CVXdPrCaBvEzT3UNGaP1V035h-Y86_Wz9asGyn5OGN2kHll0VkaZuQgB74qDtBdZ9hp9ipzAxLSOj3w1dfmd3niLVusQxroz8j8lio=\" rel=\"nofollow\" target=\"_blank\">https:\/\/edge.media-server.com\/mmc\/p\/xog3u2xy<\/a>\n      <\/p>\n<p>\n        <strong>To participate via telephone in the Q&amp;A session, register using this link:<\/strong><br \/>\n        <br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MkzTwN5x74HdjB6kMBV9eF9ErvDhDcuc1AqJopqE26gwuh6V6XROoK9jXoCWbIf6QwA7rcBSLrB7s_0oquzAItMO4pm_5bfkq0PrevHdVDnbl61rCbaM31MSWFqX6X0IJaUeixREARthrbjM-4JMIUXM_0DAFtZZnv4OdN3nIM3uNx708s02XcsatdzfiugLbv-ScK5yy2CPV5M-GwJtYDxI9DMCal9R5Hu7yaEUeOqcHT9olZoROAy0WnjQQKwR4j9IyBeF_Kl0uyYSQA9irw==\" rel=\"nofollow\" target=\"_blank\">https:\/\/register-conf.media-server.com\/register\/BIc6f9e20f129b4e789c7bc1a732488c5c<\/a>\n      <\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p>\n        <strong>Media contacts \u2013 <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fRI6ifl7c1LCK6DYPdGY3LhfegfrfyQH4BOGtzfghz-9TN5zpGVTcVjBCiqnn4Ur1iVvQBZzfc538egPB6QSdtVqZBWn6zHDms7sFI4CGUSOUGxiJ3gM1GY8elYmviEQ\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>alvotech.media@alvotech.com<\/strong><br \/>\n        <\/a><br \/>\n        <br \/>Benedikt Stefansson<br \/>Sarah MacLeod<\/p>\n<p>\n        <strong>Investor Relations contacts<\/strong><br \/>\n        <strong> \u2013 <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fRI6ifl7c1LCK6DYPdGY3ObcjpSCll7S3VICaginv4GmTPaPBhfSOWfKQGc55DO_pFtELHDS-NC2b-AFwR66m6coeNFcv0aV-Xkk97y4GkQ_8VOYxbleWNUhigXkhA1z\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <strong>alvotech.ir@alvotech.com<\/strong><br \/>\n        <\/a><br \/>\n        <br \/>Dr. Balaji V Prasad<br \/>Benedikt Stefansson<br \/>Mikaela Vilchez<\/p>\n<p>\n        <strong>Financial calendar<\/strong>\n      <\/p>\n<p>Annual or interim results will be released on the dates specified below, after the close of U.S. markets. An earnings call is held on the following day, after release of the results. Please note that all dates are subject to change.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:14%;width:14%;min-width:14%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Quarter<\/strong>\n          <\/td>\n<td style=\"max-width:43%;width:43%;min-width:43%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Date of release<\/strong>\n          <\/td>\n<td style=\"max-width:43%;width:43%;min-width:43%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Date of earnings call<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Q4 2026<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\u00a0March 10, 2027<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">March 11, 2027<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong><br \/>\n          <br \/>Upcoming events<\/strong>\n      <\/p>\n<p>Alvotech\u2019s management team will appear at several investor conferences in November 2026. Please visit our events page <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MkzTwN5x74HdjB6kMBV9eEkfMv_3O8HeCIxo6fRXXFoWSR1RS7FPLguMmwOD3Ei9owfKbmttpSmELVighpIxeHI0jkKE9dBWCRQNKZdGGEigsXK8-LJ9QQK14MhOTBV3\" rel=\"nofollow\" target=\"_blank\">https:\/\/alvotech.com\/events<\/a> to find more information about the timing of these events and how to register for live webcasts. Please note that all details are subject to change.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:40%;width:40%;min-width:40%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Date<\/strong>\n          <\/td>\n<td style=\"max-width:40%;width:40%;min-width:40%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Event<\/strong>\n          <\/td>\n<td style=\"max-width:20%;width:20%;min-width:20%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Location<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Tuesday, November 17, 2026<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">UBS Global Biopharma Conference<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">London<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Wednesday, November 18, 2026<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Jefferies Global Healthcare Conference<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">London<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Tuesday, November 24, 2026<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">DNB Carnegie Healthcare Conference<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Oslo<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\n            <strong>Wednesday, November 25, 2026<\/strong>\n          <\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">SEB Healthcare Seminar<\/td>\n<td style=\"border-right: solid black 1pt;border-bottom: solid black 1pt;vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">Stockholm<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong><br \/>\n          <br \/>About Alvotech\u00a0 <\/strong>\n      <\/p>\n<p>Alvotech is a biotechnology company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high-quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Five biosimilars are already approved and marketed in multiple global markets, including biosimilars to Humira<sup>\u00ae <\/sup>(adalimumab), Stelara<sup>\u00ae <\/sup>(ustekinumab), Simponi<sup>\u00ae <\/sup>(golimumab), Eylea<sup>\u00ae <\/sup>(aflibercept) and Prolia<sup>\u00ae<\/sup>\/Xgeva<sup>\u00ae <\/sup>(denosumab). The current development pipeline includes disclosed biosimilar candidates aimed at treating autoimmune disorders, eye disorders, and cancer. Alvotech has formed a network of strategic commercial partnerships to provide global reach and leverage local expertise in markets that include the United States, Europe, Japan, China, and other Asian countries and large parts of South America, Africa and the Middle East. For more information, please visit https:\/\/www.alvotech.com. None of the information on the Alvotech website shall be deemed part of this press release.<\/p>\n<p>For more information, please visit our <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=r0SkUDpMbrbQ8S3MVylrcVA2roJ6GK4yKHhgzpJydZzbVie9uM6_eit8CxVY9ZZHldiszZXJifDcG0AqHAixwLWNDvFrXpnrUc2mIB4lMMyUYZXTvbROYSC70ZqCUjUjmZjRnFDwijIQ-hxQoYCFavqV6YpjvJoS9czz10Cj-8-5x2dZlm4ywjcW9Zl7JVEUeZdDi3NZIyfTgvk6g0OI963sb5inUHSbCdysaYuF794=\" rel=\"nofollow\" target=\"_blank\">website<\/a>\u00a0or follow us on social media on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qHiR8o7YXEfBiqL7yr49VIiMyIQUTpPHvLeypG_nO42WJfhPAzQWcnVVH3_RW2w3BSXvLadKtd0hazVDZsrVMqhvSPbFP4eYTRyvSNQZUa8mTDA9oCIhnZmVw7TNhYfbiFOUlolW_FXPyBaehE8RVhKfHCpCTYi_W--x6gt8J2hDAtfCU8GTtl_RbjqokNID9oMe1cV7v4U_3ZYLEHJQA6EpstptIZHjIAt610q41NzzwCUrfzpfB9thW7a-Bvn9\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jVzr-NREsEVDo1CTlIzkruzgsEyMAQ0TxRlMneSQLunQQCuPkM2bwqtJoewBr4VpOFApTx4P8e3VS6qLiKra3qbVFeAkvYtHdz-MK-4pb-miA9-g8WuJCTgmKvMFFCgQieN6PJuXuqNkEGTJDwlmefs9UijrQhcCMv9MaZzQ6Ui11E8DUa-Gyl99hBRjAuJIBO3HOuFvmYPrkW_PC4BqiLY2l3-Doi5Lh1PDIuR9MFtN8r1yr38DmmIRVx8YzWMs\" rel=\"nofollow\" target=\"_blank\">Facebook<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=FNuPSnRysYYwTMqIbszssnQ8FvQCdqv-v1lUa8HjcP68V-z-3n46W3exBdesXfafVF3in1gx-Am5d3CyOrktpUZ33-oDTw3nko1kJtjpx1Fj7prpr0UHWem0cz4ByhG0cK6dvwY4BIRYYJmsFFhOFs7bHffXl1deUEaLkSeS-wEImj8RmM5TAcPtmv7lYNdyZBmAPWp8837PDHhEkEn5j2UpwUMuCWS-32EX_v6sYhuX9B5wlkUPsAMjXuUbrcbL\" rel=\"nofollow\" target=\"_blank\">Instagram<\/a>, and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pETpb4CEeiA2xEyM1tHxwnOq6Uz-gd2ky5y1cRT2jZYZ-Kk2TXdnUs-UfIuh9dW049H_UBBrrVWlqhQZPxuW-dXgqMcU9gkEVp1wFZ-4Gc9oUV9q_KYrUirITNWnAq8SiCFBT-YqUFvZ1xBvh5-oWEcI4G302uYuixMaY4sncWk7zTNK3_WSlIBIZTpfVSJVTQKAzALgNV_zungSIYmB5VY5iF2WJBx7d6YwAJyEnrYP9NzZ89KPIA_z0Sm-GIA0\" rel=\"nofollow\" target=\"_blank\">YouTube<\/a>.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong>\n      <\/p>\n<p>Certain statements in this communication may be considered \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements include, for example, Alvotech\u2019s expectations regarding competitive advantages, business prospects and opportunities including pipeline product development, future plans and intentions, regulatory submissions, review and interactions, the potential approval and commercial launch of its product candidates, the timing of regulatory approval, market launches and financial projections. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Alvotech and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Alvotech\u2019s control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to factors set forth in the sections entitled \u201cRisk Factors\u201d and \u201cCautionary Note Regarding Forward-Looking Statements\u201d in documents that Alvotech may from time-to-time file or furnish with the SEC. There may be additional risks that Alvotech does not presently know or that Alvotech currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Alvotech does not undertake any duty to update these forward-looking statements or to inform the recipient of any matters of which any of them becomes aware of which may affect any matter referred to in this communication. Alvotech disclaims any and all liability for any loss or damage (whether foreseeable or not) suffered or incurred by any person or entity as a result of anything contained or omitted from this communication and such liability is expressly disclaimed.<\/p>\n<p>\n        <strong>Non IFRS Financial Measures<\/strong>\n      <\/p>\n<p>This Presentation may include projections of certain financial measures not presented in accordance with International Financial Reporting Standards (\u201cIFRS\u201d) including, but not limited to, Adjusted Revenues, EBITDA and certain ratios and other metrics derived therefrom. These non-IFRS financial measures are not measures of financial performance in accordance with IFRS and may exclude items that are significant in understanding and assessing the Company\u2019s financial results. Therefore, these measures should not be considered in isolation or as an alternative to net income, cash flows from operations or other measures of profitability, liquidity or performance under IFRS. You should be aware that the Company\u2019s presentation of these measures may not be comparable to similarly-titled measures used by other companies. The Company believes these non-IFRS measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company\u2019s financial condition and results of operations. The Company believes that the use of these non-IFRS financial measures provide an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company\u2019s financial measures with other similar companies, many of which present similar non-IFRS financial measures to investors. These non-IFRS financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income are excluded or included in determining these non-IFRS financial measures. Due to the high variability and difficulty in making accurate forecasts and projections of some of the information excluded from these projected measures, together with some of the excluded information not being ascertainable or accessible, the Company is unable to quantify certain amounts that would be required to be included in the most directly comparable IFRS financial measures without unreasonable effort. Consequently, no disclosure of estimated comparable IFRS measures is included and no reconciliation of the forward-looking non-IFRS financial measures is included. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.<\/p>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"8\" style=\"vertical-align: bottom\">\n            <strong>Reported to Adjusted Reconciliation for the nine months ended September 30, 2026 and 2025<\/strong><br \/>\n            \n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"8\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2026 9M<\/strong><br \/>\n            \n          <\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2025 9M<\/strong><br \/>\n            \n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:26%;width:26%;min-width:26%;vertical-align: top\">\n            <em>USD millions<\/em>\n          <\/td>\n<td style=\"max-width:12%;width:12%;min-width:12%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>Reported<\/strong>\n          <\/td>\n<td style=\"max-width:12%;width:12%;min-width:12%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>Adjustment<\/strong>\n          <\/td>\n<td style=\"max-width:12%;width:12%;min-width:12%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>Adjusted<\/strong>\n          <\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;vertical-align: top\">\u00a0<\/td>\n<td style=\"max-width:12%;width:12%;min-width:12%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>Reported<\/strong>\n          <\/td>\n<td style=\"max-width:12%;width:12%;min-width:12%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>Adjustment<\/strong>\n          <\/td>\n<td style=\"max-width:12%;width:12%;min-width:12%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>Adjusted<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">Product and Service Revenue<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">164.2<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">&#8211;<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">164.2<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">237.4<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">&#8211;<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">237.4<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">License and Other Revenue<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">158.9<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">&#8211;<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">158.9<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: top\">182.4<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: top\">0.3<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: top\">182.6<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">Other Income<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">0.4<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">&#8211;<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">0.4<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: top\">0.3<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: top\">(0.3)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: top\">&#8211;<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">\n            <strong>Total revenue<\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>323.4 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>&#8211; <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>323.4 <\/strong>\n          <\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>420.0 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>&#8211; <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>420.0 <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">Cost of Product Revenue<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(150.1)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">1.1<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(149.0)<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(174.3)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">1.4<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(172.9)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">R&amp;D<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(63.6)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(0.5)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(64.1)<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(144.5)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(7.6)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(152.1)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">G&amp;A<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(98.9)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">35.0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(63.9)<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(71.3)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">16.8<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(54.5)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">\n            <strong>Operating Profit (Loss)<\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>10.8 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>35.6 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>46.3 <\/strong>\n          <\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>30.0 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>10.7 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>40.6 <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">D&amp;A<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(32.0)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">&#8211;<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(32.0)<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(27.4)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">0.0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(27.4)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">\n            <strong>EBITDA<\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>42.8 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>35.6 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>78.3 <\/strong>\n          <\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>57.4 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>10.7 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>68.0 <\/strong>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"8\" style=\"vertical-align: bottom\">\n            <strong>Reported to Adjusted Reconciliation for the quarters ended September 30, 2026 and 2025<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td colspan=\"8\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2026 3Q<\/strong><br \/>\n            \n          <\/td>\n<td style=\"text-align: center;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td colspan=\"3\" style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle;vertical-align: bottom\">\n            <strong>2025 3Q<\/strong><br \/>\n            \n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:26%;width:26%;min-width:26%;vertical-align: top\">\n            <em>USD millions<\/em>\n          <\/td>\n<td style=\"max-width:12%;width:12%;min-width:12%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>Reported<\/strong>\n          <\/td>\n<td style=\"max-width:12%;width:12%;min-width:12%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>Adjustment<\/strong>\n          <\/td>\n<td style=\"max-width:12%;width:12%;min-width:12%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>Adjusted<\/strong>\n          <\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;vertical-align: top\">\u00a0<\/td>\n<td style=\"max-width:12%;width:12%;min-width:12%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>Reported<\/strong>\n          <\/td>\n<td style=\"max-width:12%;width:12%;min-width:12%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>Adjustment<\/strong>\n          <\/td>\n<td style=\"max-width:12%;width:12%;min-width:12%;text-align: right;vertical-align: middle;vertical-align: top\">\n            <strong>Adjusted<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">Product and Service Revenue<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">58.2<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">&#8211;<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">58.2<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">32.6<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">&#8211;<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">32.6<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">License and Other Revenue<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">53.2<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">&#8211;<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">53.2<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">81.1<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">&#8211;<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">81.1<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">Other Income<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">0.2<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">&#8211;<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">0.2<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">0.1<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">&#8211;<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">0.1<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">\n            <strong>Total revenue<\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>111.6 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>&#8211; <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>111.6 <\/strong>\n          <\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>113.9 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>&#8211; <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>113.9 <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">Cost of Product Revenue<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(51.8)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">0.2<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(51.6)<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(35.0)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">0.1<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(34.9)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">R&amp;D<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(17.2)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">0.2<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(17.0)<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(51.6)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(3.5)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(55.1)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">G&amp;A<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(29.7)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">6.9<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(22.8)<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(25.9)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">6.2<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(19.8)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">\n            <strong>Operating Profit (Loss)<\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>12.8 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>7.3 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>20.1 <\/strong>\n          <\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>1.3 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>2.8 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>4.1 <\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">D&amp;A<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(11.4)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">&#8211;<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(11.4)<\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(10.3)<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">0.0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">(10.3)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom\">\n            <strong>EBITDA<\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>24.2 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>7.3 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>31.5 <\/strong>\n          <\/td>\n<td style=\"vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>11.6 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>2.8 <\/strong>\n          <\/td>\n<td style=\"text-align: right;vertical-align: middle;vertical-align: bottom\">\n            <strong>14.4 <\/strong>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"5\" style=\"vertical-align: top\">\n            <strong>Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income or Loss for the nine months ended September 30, 2026 and 2025<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:60%;width:60%;min-width:60%\">\n            <em>USD in thousands, except for per share amounts<\/em>\n          <\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%\">\u00a0<\/td>\n<td style=\"max-width:18%;width:18%;min-width:18%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>Nine months ended<br \/>September 30,<br \/>2026<\/strong>\n          <\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%\">\u00a0<\/td>\n<td style=\"max-width:18%;width:18%;min-width:18%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>Nine months ended<br \/>September 30,<br \/>2025<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>Product and service revenue<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">164,152<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">237,382<\/td>\n<\/tr>\n<tr>\n<td>License and other revenue<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">158,883<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">182,366<\/td>\n<\/tr>\n<tr>\n<td>Other income<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">379<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">261<\/td>\n<\/tr>\n<tr>\n<td>Cost of product and service revenue<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(150,103)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(174,278)<\/td>\n<\/tr>\n<tr>\n<td>Research and development expenses<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(63,613)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(144,508)<\/td>\n<\/tr>\n<tr>\n<td>General and administrative expenses<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">(98,919)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">(71,271)<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Operating profit <\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">10,779<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">29,952<\/td>\n<\/tr>\n<tr>\n<td>Effects resulting from business combination<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">\u2014<\/td>\n<td style=\"text-align: right;vertical-align: middle\">\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">7,977<\/td>\n<\/tr>\n<tr>\n<td>Finance income<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">8,980<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">170,687<\/td>\n<\/tr>\n<tr>\n<td>Finance costs<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(168,684)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(108,449)<\/td>\n<\/tr>\n<tr>\n<td>Exchange rate differences<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(5,280)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(21,226)<\/td>\n<\/tr>\n<tr>\n<td>Net gain on modification and extinguishment of financial liabilities<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\u2014<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">17,703<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Non-operating (loss) \/ profit <\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">(164,984)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">66,692<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>(Loss) \/ profit before taxes<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(154,205)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">96,644<\/td>\n<\/tr>\n<tr>\n<td>Income tax benefit<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">13,546<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">39,822<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>(Loss) \/ profit for the period<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: right;vertical-align: middle\">(140,659)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: right;vertical-align: middle\">136,466<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Other comprehensive (loss) \/ profit<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\n            <em>Item that will be reclassified to profit or loss in subsequent periods:<\/em>\n          <\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>Exchange rate differences on translation of foreign operations<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: right;vertical-align: middle\">(2,794)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: right;vertical-align: middle\">3,310<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Total comprehensive (loss) \/profit<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: right;vertical-align: middle\">(143,453)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: right;vertical-align: middle\">139,776<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>(Loss) \/ profit per share<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>Basic (loss) \/ profit for the period per share<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(0.45)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">0.47<\/td>\n<\/tr>\n<tr>\n<td>Diluted (loss) \/ profit for the period per share<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: right;vertical-align: middle\">(0.45)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: right;vertical-align: middle\">0.47<\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"5\" style=\"vertical-align: top\">\n            <strong>Unaudited Condensed Consolidated Interim Statements of Financial Position as of September 30, 2026 and December 31, 2025<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:60%;width:60%;min-width:60%\">\n            <em>USD in thousands <\/em>\n          <\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:18%;width:18%;min-width:18%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:18%;width:18%;min-width:18%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td rowspan=\"2\">\n            <strong>Non-current assets<\/strong>\n          <\/td>\n<td rowspan=\"2\">\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle\">\n            <strong>September 30<\/strong>\n          <\/td>\n<td rowspan=\"2\">\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle\">\n            <strong>December 31<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>2026<\/strong>\n          <\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>2025<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>Property, plant and equipment<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">367,141<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">356,398<\/td>\n<\/tr>\n<tr>\n<td>Right-of-use assets<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">145,349<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">138,294<\/td>\n<\/tr>\n<tr>\n<td>Goodwill<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">12,377<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">12,835<\/td>\n<\/tr>\n<tr>\n<td>Other intangible assets<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">174,340<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">81,834<\/td>\n<\/tr>\n<tr>\n<td>Contract assets<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">177,885<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">122,934<\/td>\n<\/tr>\n<tr>\n<td>Other long-term assets<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">18,200<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">8,578<\/td>\n<\/tr>\n<tr>\n<td>Deferred tax assets<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">208,038<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">192,211<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Total non-current assets<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">1,103,330<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">913,084<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Current assets<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>Inventories<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">242,252<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">220,054<\/td>\n<\/tr>\n<tr>\n<td>Trade receivables<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">65,179<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">69,740<\/td>\n<\/tr>\n<tr>\n<td>Contract assets<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">54,978<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">64,440<\/td>\n<\/tr>\n<tr>\n<td>Other current assets<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">83,584<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">46,984<\/td>\n<\/tr>\n<tr>\n<td>Receivables from related parties<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">5,252<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">438<\/td>\n<\/tr>\n<tr>\n<td>Cash and cash equivalents<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">61,468<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">172,359<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Total current assets<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">512,713<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">574,015<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Total assets<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: right;vertical-align: middle\">1,616,043<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: right;vertical-align: middle\">1,487,099<\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"5\" style=\"vertical-align: top\">\n            <strong>Unaudited Condensed Consolidated Interim Statements of Financial Position as of September 30, 2026 and December 31, 2025<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:60%;width:60%;min-width:60%\">\n            <em>USD in thousands <\/em>\n          <\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:18%;width:18%;min-width:18%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:18%;width:18%;min-width:18%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td rowspan=\"2\">\n            <strong>Equity<\/strong>\n          <\/td>\n<td rowspan=\"2\">\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle\">\n            <strong>September 30<\/strong>\n          <\/td>\n<td rowspan=\"2\">\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle\">\n            <strong>December 31<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>2026<\/strong>\n          <\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>2025<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>Share capital<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">3,380<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">2,929<\/td>\n<\/tr>\n<tr>\n<td>Share premium<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">2,269,996<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">2,105,691<\/td>\n<\/tr>\n<tr>\n<td>Other reserves<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">11,248<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">15,331<\/td>\n<\/tr>\n<tr>\n<td>Translation reserve<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(1,442)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">1,352<\/td>\n<\/tr>\n<tr>\n<td>Accumulated deficit<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">(2,550,449)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">(2,409,790)<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Total equity<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: right;vertical-align: middle\">(267,267)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: right;vertical-align: middle\">(284,487)<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Non-current liabilities<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>Borrowings<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">1,341,286<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">1,262,147<\/td>\n<\/tr>\n<tr>\n<td>Derivative financial liabilities<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">90,540<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">53,994<\/td>\n<\/tr>\n<tr>\n<td>Lease liabilities<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">151,559<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">137,999<\/td>\n<\/tr>\n<tr>\n<td>Contract liabilities<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">4,184<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">5,500<\/td>\n<\/tr>\n<tr>\n<td>Deferred tax liability<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">7,943<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">7,868<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Total non-current liabilities<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">1,595,512<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">1,467,508<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Current liabilities<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>Trade and other payables<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">90,214<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">126,124<\/td>\n<\/tr>\n<tr>\n<td>Lease liabilities<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">12,969<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">12,078<\/td>\n<\/tr>\n<tr>\n<td>Current maturities of borrowings<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">54,967<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">36,921<\/td>\n<\/tr>\n<tr>\n<td>Liabilities to related parties<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">3,368<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">3,325<\/td>\n<\/tr>\n<tr>\n<td>Contract liabilities<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">3,742<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">30,364<\/td>\n<\/tr>\n<tr>\n<td>Taxes payable<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">2,014<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">1,041<\/td>\n<\/tr>\n<tr>\n<td>Other current liabilities<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">120,524<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">94,225<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Total current liabilities<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">287,798<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">304,078<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Total liabilities<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: right;vertical-align: middle\">1,883,310<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: right;vertical-align: middle\">1,771,586<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Total equity and liabilities<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: right;vertical-align: middle\">1,616,043<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: right;vertical-align: middle\">1,487,099<\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"5\" style=\"vertical-align: top\">\n            <strong>Unaudited Condensed Consolidated Interim Statements of Cash Flows for the nine months ended September 30, 2026 and 2025<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:60%;width:60%;min-width:60%\">\n            <em>USD in thousands <\/em>\n          <\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:18%;width:18%;min-width:18%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"max-width:18%;width:18%;min-width:18%;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Cash flows from operating activities<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>Nine months ended<br \/>September 30, 2026<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>Nine months ended<br \/>September 30, 2025<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>(Loss) \/ profit for the period<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(140,659)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">136,466<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Adjustments for non-cash items:<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<tr>\n<td>Depreciation, amortization and impairment<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">31,976<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">27,438<\/td>\n<\/tr>\n<tr>\n<td>Effects resulting from business combination<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">\u2014<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(7,977)<\/td>\n<\/tr>\n<tr>\n<td>Change in allowance for receivables<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">569<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">703<\/td>\n<\/tr>\n<tr>\n<td>Change in inventory reserves<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">5,707<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">8,713<\/td>\n<\/tr>\n<tr>\n<td>Share-based payments<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">7,094<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">6,166<\/td>\n<\/tr>\n<tr>\n<td>Change in commercial provision<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">20,200<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">\u2014<\/td>\n<\/tr>\n<tr>\n<td>Net gain on modification and extinguishment of financial liabilities<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">\u2014<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(17,703)<\/td>\n<\/tr>\n<tr>\n<td>Finance income<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(8,980)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(170,687)<\/td>\n<\/tr>\n<tr>\n<td>Finance costs<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">168,684<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">108,449<\/td>\n<\/tr>\n<tr>\n<td>Exchange rate difference<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">5,280<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">21,226<\/td>\n<\/tr>\n<tr>\n<td>Income tax benefit<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">(13,546)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">(39,822)<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Operating cash flow before movement in working capital<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">76,325<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">72,972<\/td>\n<\/tr>\n<tr>\n<td>Increase in inventories<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(27,905)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(85,871)<\/td>\n<\/tr>\n<tr>\n<td>Decrease in trade receivables<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">3,992<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">100,235<\/td>\n<\/tr>\n<tr>\n<td>Increase in receivables with related parties<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(4,814)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(882)<\/td>\n<\/tr>\n<tr>\n<td>Increase in contract assets<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(46,649)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(29,333)<\/td>\n<\/tr>\n<tr>\n<td>Increase in other assets<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(37,673)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(8,169)<\/td>\n<\/tr>\n<tr>\n<td>(Decrease) \/ increase in trade and other payables<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(35,446)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">25,092<\/td>\n<\/tr>\n<tr>\n<td>Decrease in contract liabilities<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(27,324)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(49,694)<\/td>\n<\/tr>\n<tr>\n<td>Increase \/ (decrease) in liabilities with related parties<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">43<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(1,205)<\/td>\n<\/tr>\n<tr>\n<td>Increase in other liabilities<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">2,840<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">12,070<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Cash (used in) \/ from operations<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(96,611)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">35,215<\/td>\n<\/tr>\n<tr>\n<td>Interest received<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">806<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">294<\/td>\n<\/tr>\n<tr>\n<td>Interest paid<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(109,061)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(22,338)<\/td>\n<\/tr>\n<tr>\n<td>Income tax paid<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">(746)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">(455)<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Net cash (used in) \/ from operating activities<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(205,612)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">12,716<\/td>\n<\/tr>\n<\/table>\n<p>\n        \n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td colspan=\"5\" style=\"vertical-align: top\">\n            <strong>Unaudited Condensed Consolidated Interim Statements of Cash Flows for the nine months ended September 30, <\/strong><br \/>\n            <strong>2026 and 2025<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:60%;width:60%;min-width:60%;vertical-align: bottom\">\n            <em>USD in thousands <\/em>\n          <\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%\">\u00a0<\/td>\n<td style=\"max-width:18%;width:18%;min-width:18%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>Nine months ended<br \/>September 30, 2026<\/strong>\n          <\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%\">\u00a0<\/td>\n<td style=\"max-width:18%;width:18%;min-width:18%;border-bottom: solid black 1pt;text-align: center;vertical-align: middle\">\n            <strong>Nine months ended<br \/>September 30, 2025<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Cash flows from investing activities<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<td style=\"text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle\">\n            <strong>\u00a0<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td>Acquisition of property, plant and equipment<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(40,357)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(55,731)<\/td>\n<\/tr>\n<tr>\n<td>Acquisition of intangible assets<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(88,164)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(24,632)<\/td>\n<\/tr>\n<tr>\n<td>Net cash outflow on acquisition of subsidiary<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">\u2014<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(14,036)<\/td>\n<\/tr>\n<tr>\n<td>Proceeds from the sale in joint venture<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">\u2014<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">5,950<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Net cash used in investing activities<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(128,521)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(88,449)<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Cash flows from financing activities<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle\">\u00a0<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: center;vertical-align: middle\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td>Repayments of borrowings<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(33,585)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(18,402)<\/td>\n<\/tr>\n<tr>\n<td>Repayments of principal portion of lease liabilities<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(9,274)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(8,285)<\/td>\n<\/tr>\n<tr>\n<td>Proceeds from new borrowings<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">113,676<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">12,028<\/td>\n<\/tr>\n<tr>\n<td>Transaction cost from new borrowings<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(2,811)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">\u2014<\/td>\n<\/tr>\n<tr>\n<td>Gross proceeds from equity offering<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">164,600<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">82,481<\/td>\n<\/tr>\n<tr>\n<td>Fees from equity offering<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">(8,521)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">(3,759)<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Net cash from financing activities<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">224,085<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">64,063<\/td>\n<\/tr>\n<tr>\n<td>Decrease in cash and cash equivalents<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(110,048)<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">(11,670)<\/td>\n<\/tr>\n<tr>\n<td>Cash and cash equivalents at the beginning of the period<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">172,359<\/td>\n<td>\u00a0<\/td>\n<td style=\"text-align: right;vertical-align: middle\">51,428<\/td>\n<\/tr>\n<tr>\n<td>Effect of movements in exchange rates on cash held<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">(843)<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt;text-align: right;vertical-align: middle\">3,090<\/td>\n<\/tr>\n<tr>\n<td>\n            <strong>Cash and cash equivalents at the end of the period<\/strong>\n          <\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: right;vertical-align: middle\">61,468<\/td>\n<td>\u00a0<\/td>\n<td style=\"border-bottom: double black 3pt;text-align: right;vertical-align: middle\">42,848<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        <sup>______________________________\u00a0<br \/><sub>1<\/sub><\/sup><br \/>\n        <sub>Supplemental information, including the management presentation, is provided solely for reference and is not part of this SEC form 6\u2011K and the form 6\u2011K should not be read together with, or construed as referring to, the supplemental information.<br \/><sup>2<\/sup> Unless otherwise specified, all figures presented in the Financial Highlights are on an adjusted basis and exclude items that are not indicative of our ongoing operating performance. See the tables on \u2018Reported to Adjusted Reconciliation\u2019 and disclaimer on \u2018Non IFRS Financial Measures\u2019, at the end of this press release. As a foreign private issuer, Alvotech is not required to, and does not, prepare or file quarterly financial statements under IFRS or with the SEC. The financial information included in this Form 6-K reflects management\u2019s current estimates and is presented for the purpose of providing an interim business update.<\/sub>\n      <\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwMzE0NyM0MDI1NjI1NzAjMjIzMzgzMw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/ZDRhNzUxMmItMGI4Yi00ZTQ4LWJhNGMtZGIxZjFjMDk3ZjQ2LTEyNDUzODYtMjAyNi0xMS0xMS1lbg==\/tiny\/Alvotech.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>REYKJAVIK, Iceland, Nov. 11, 2026 (GLOBE NEWSWIRE) &#8212; Alvotech (NASDAQ: ALVO; ALVO-SDB) (\u201cAlvotech\u201d or the \u201cCompany\u201d), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the nine months to September 30, 2026, and provided a business update. Supplemental information, including the management presentation providing additional details and a business update, is available on our website: https:\/\/alvotech.com\/financials.1 Financial Highlights for the Nine Months to September 30, 20262 Adjusted total revenue2 was $323.4 million compared to $420.0 million in the same period last year. Gross Margin was 54% compared to 59% in the same period last year. Adjusted EBITDA2 was $78.3 million compared to $68.0 million in the same period &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1020131","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REYKJAVIK, Iceland, Nov. 11, 2026 (GLOBE NEWSWIRE) &#8212; Alvotech (NASDAQ: ALVO; ALVO-SDB) (\u201cAlvotech\u201d or the \u201cCompany\u201d), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the nine months to September 30, 2026, and provided a business update. Supplemental information, including the management presentation providing additional details and a business update, is available on our website: https:\/\/alvotech.com\/financials.1 Financial Highlights for the Nine Months to September 30, 20262 Adjusted total revenue2 was $323.4 million compared to $420.0 million in the same period last year. Gross Margin was 54% compared to 59% in the same period last year. Adjusted EBITDA2 was $78.3 million compared to $68.0 million in the same period &hellip; Continue reading &quot;Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-11T22:51:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwMzE0NyM0MDI1NjI1NzAjMjIzMzgzMw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update\",\"datePublished\":\"2026-11-11T22:51:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\\\/\"},\"wordCount\":2593,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTMwMzE0NyM0MDI1NjI1NzAjMjIzMzgzMw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\\\/\",\"name\":\"Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTMwMzE0NyM0MDI1NjI1NzAjMjIzMzgzMw==\",\"datePublished\":\"2026-11-11T22:51:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTMwMzE0NyM0MDI1NjI1NzAjMjIzMzgzMw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTMwMzE0NyM0MDI1NjI1NzAjMjIzMzgzMw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/","og_locale":"en_US","og_type":"article","og_title":"Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update - Market Newsdesk","og_description":"REYKJAVIK, Iceland, Nov. 11, 2026 (GLOBE NEWSWIRE) &#8212; Alvotech (NASDAQ: ALVO; ALVO-SDB) (\u201cAlvotech\u201d or the \u201cCompany\u201d), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the nine months to September 30, 2026, and provided a business update. Supplemental information, including the management presentation providing additional details and a business update, is available on our website: https:\/\/alvotech.com\/financials.1 Financial Highlights for the Nine Months to September 30, 20262 Adjusted total revenue2 was $323.4 million compared to $420.0 million in the same period last year. Gross Margin was 54% compared to 59% in the same period last year. Adjusted EBITDA2 was $78.3 million compared to $68.0 million in the same period &hellip; Continue reading \"Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/","og_site_name":"Market Newsdesk","article_published_time":"2026-11-11T22:51:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwMzE0NyM0MDI1NjI1NzAjMjIzMzgzMw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update","datePublished":"2026-11-11T22:51:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/"},"wordCount":2593,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwMzE0NyM0MDI1NjI1NzAjMjIzMzgzMw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/","name":"Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwMzE0NyM0MDI1NjI1NzAjMjIzMzgzMw==","datePublished":"2026-11-11T22:51:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwMzE0NyM0MDI1NjI1NzAjMjIzMzgzMw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTMwMzE0NyM0MDI1NjI1NzAjMjIzMzgzMw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alvotech-announces-financial-results-for-the-nine-months-to-september-30-2026-with-a-business-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1020131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1020131"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1020131\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1020131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1020131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1020131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}